Key result
Anthracycline-containing chemotherapy in older women with breast cancer was associated with an increased risk of congestive heart failure (HR 1.25; 95% CI 1.07-1.46) compared to no chemotherapy.
Why the study?
Does anthracycline-containing chemotherapy increase the risk of cardiac toxicity in older women with breast cancer?
Population
19,478 women aged >65 diagnosed with breast cancer in 1991-1997 from 16 regions in the Surveillance…
Comparison
Anthracycline-containing chemotherapy vs No chemotherapy
Design
Cohort
Follow-up
up to 16 years
Authors
Loading...
Supports HF surveillance in older breast cancer patients receiving anthracyclines; leaves open causality and cardioprotection trials.
Cohort (n=19,478)
Yes
Does anthracycline-containing chemotherapy increase the risk of cardiac toxicity in older women with breast cancer?
Hazard Ratio: 1.25 (95% CI 1.07–1.46)
Absolute Event Rate: 31.9% vs 27.2%
In older women with breast cancer, anthracycline-containing chemotherapy is associated with a significantly increased long-term risk of congestive heart failure and cardiomyopathy.
Du et al. (2009) conducted a cohort in breast cancer (n=19,478). Anthracycline-containing chemotherapy vs. No chemotherapy was evaluated on congestive heart failure (HR 1.25, 95% CI 1.07-1.46). Anthracycline-containing chemotherapy in older women with breast cancer was associated with an increased risk of congestive heart failure (HR 1.25; 95% CI 1.07-1.46) compared to no chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: